Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
005257.KS
Top 10 Correlated ETFs
005257.KS
Top 10 Correlated Stocks
005257.KS
Financial details
Company Rating
Buy
Market Cap
752.13B
Income
32.37B
Revenue
2057.37B
Book val./share
12533.11
Cash/share
-
Dividend
400
Dividend %
0.95%
Employees
154
Optionable
No
Shortable
Yes
Earnings
-
P/E
104.84
Forward P/E
-
PEG
-12.45
P/S
1.65
P/B
3.36
P/C
-
P/FCF
169.24
Quick Ratio
-
Current Ratio
1.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
599.64
EPS next Y
-
EPS next Q
-
EPS this Y
-67.78%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.05%
Revenue last 5Y
4.67%
Revenue Q/Q
2.93%
EPS Q/Q
224.24%
-
-
-
-
SMA20
-19.94%
SMA50
-30.95%
SMA100
-6.46%
Inst Own
-
Inst Trans
-
ROA
1%
ROE
3%
ROC
0.05%
Gross Margin
35%
Oper. Margin
6%
Profit Margin
2%
Payout
99%
Shs Outstand
467.54K
Shs Float
24.38M
-
-
-
-
Target Price
-
52W Range
35650.0-100000.0
52W High
-57.85%
52W Low
+18.23%
RSI
44.55
Rel Volume
4.13
Avg Volume
3.53K
Volume
14.56K
Perf Week
1.44%
Perf Month
-23.36%
Perf Quarter
-4.1%
Perf Half Y
-9.55%
-
-
-
-
Beta
1.21346
-
-
Volatility
3405.92%, 4967.81%
Prev Close
-8.96%
Price
42150
Change
18.23%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 32.6K | 34.45K | 33.93K | 38.26K | 40.69K | |
| Net income per share | 965.06 | 410.97 | 65.82 | 3.8K | 1.22K | |
| Operating cash flow per share | 3.22K | 837.75 | 170.26 | 848.76 | 2.29K | |
| Free cash flow per share | -1.48K | -2.46K | -3.5K | -2.17K | -841.62 | |
| Cash per share | 6.05K | 6.04K | 4.94K | 11.35K | 8.81K | |
| Book value per share | 18.09K | 17.9K | 18.09K | 20.46K | 22.67K | |
| Tangible book value per share | 29.52K | 29.39K | 30.41K | 30.26K | 30.46K | |
| Share holders equity per share | 18.09K | 17.9K | 18.09K | 20.46K | 22.67K | |
| Interest debt per share | 15.7K | 18.03K | 19.45K | 21.85K | 21.13K | |
| Market cap | 1114.37B | 734.67B | 795.34B | 4897.83B | 1949.37B | |
| Enterprise value | 1537.16B | 1276.34B | 1474.26B | 5407.74B | 2541.79B | |
| P/E ratio | 25.7 | 39.78 | 268.93 | 28.65 | 35.27 | |
| Price to sales ratio | 0.76 | 0.47 | 0.52 | 2.85 | 1.06 | |
| POCF ratio | 7.71 | 19.52 | 103.96 | 128.42 | 18.79 | |
| PFCF ratio | -16.73 | -6.66 | -5.05 | -50.2 | -51.21 | |
| P/B Ratio | 1.37 | 0.91 | 0.98 | 5.33 | 1.9 | |
| PTB ratio | 1.37 | 0.91 | 0.98 | 5.33 | 1.9 | |
| EV to sales | 1.05 | 0.82 | 0.97 | 3.15 | 1.38 | |
| Enterprise value over EBITDA | 12.41 | 11.92 | 15.52 | 18.93 | 12.86 | |
| EV to operating cash flow | 10.64 | 33.91 | 192.7 | 141.79 | 24.49 | |
| EV to free cash flow | -23.08 | -11.56 | -9.37 | -55.42 | -66.77 | |
| Earnings yield | 0.04 | 0.03 | 0 | 0.03 | 0.03 | |
| Free cash flow yield | -0.06 | -0.15 | -0.2 | -0.02 | -0.02 | |
| Debt to equity | 0.55 | 0.52 | 0.58 | 0.24 | 0.42 | |
| Debt to assets | 0.44 | 0.45 | 0.46 | 0.48 | 0.45 | |
| Net debt to EBITDA | 3.41 | 5.06 | 7.15 | 1.78 | 3 | |
| Current ratio | 2.09 | 1.73 | 1.66 | 1.39 | 1.54 | |
| Interest coverage | 8.06 | 2.77 | 1.65 | 2.91 | 3.14 | |
| Income quality | 3.33 | 2.04 | 2.59 | 0.22 | 1.88 | |
| Dividend Yield | 0.02 | 0.03 | 0.02 | 0 | 0.02 | |
| Payout ratio | 0.51 | 1.2 | 6.18 | 0.13 | 0.58 | |
| Sales general and administrative to revenue | 0.02 | 0.04 | 0.03 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | |
| Intangibles to total assets | 0.04 | 0.05 | 0.05 | 0.1 | 0.15 | |
| Capex to operating cash flow | -1.46 | -3.93 | -21.57 | -3.56 | -1.37 | |
| Capex to revenue | -0.14 | -0.1 | -0.11 | -0.08 | -0.08 | |
| Capex to depreciation | -5.12 | -3.13 | -2.9 | -2.57 | -2.27 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 19.82K | 12.87K | 5.18K | 41.85K | 24.97K | |
| ROIC | 0.06 | 0.02 | 0.01 | 0.03 | 0.03 | |
| Return on tangible assets | 0.02 | 0.01 | 0 | 0.06 | 0.02 | |
| Graham Net | -13.37K | -15.32K | -18.21K | -18.1K | -20.66K | |
| Working capital | 622.28B | 482.8B | 447.31B | 433.03B | 498.95B | |
| Tangible asset value | 1326.51B | 1320.53B | 1366.64B | 1359.56B | 1377.48B | |
| Net current asset value | 70.34B | -30.89B | -143.62B | -31.9B | -161.24B | |
| Invested capital | 0.85 | 0.99 | 1.05 | 1.04 | 0.9 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 186.66B | 166.04B | 155.93B | 161.83B | 155.41B | |
| Average inventory | 492.81B | 460.32B | 471.46B | 489.14B | 498.07B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 73.29 | 54.4 | 50.01 | 49.68 | 44.87 | |
| Days of inventory on hand | 172.06 | 137.9 | 151.26 | 150.15 | 152.68 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.98 | 6.71 | 7.3 | 7.35 | 8.14 | |
| Inventory turnover | 2.12 | 2.65 | 2.41 | 2.43 | 2.39 | |
| ROE | 0.05 | 0.02 | 0 | 0.19 | 0.05 | |
| Capex per share | -4.7K | -3.29K | -3.67K | -3.02K | -3.14K |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 7.69K | 10.17K | 11.8K | 6.3K | 6.42K | |
| Net income per share | 294.74 | 31.21 | 448 | 254.14 | -78.34 | |
| Operating cash flow per share | -805.16 | 699.06 | 433.31 | 1.11K | 259.95 | |
| Free cash flow per share | -1.48K | -42.22 | -128.86 | 451.32 | -106.67 | |
| Cash per share | 11.65K | 10.43K | 8.8K | 4.95K | 0 | |
| Book value per share | 20.56K | 20.59K | 21.26K | 12.74K | 12.53K | |
| Tangible book value per share | 30.26K | 30.34K | 31.72K | 17.11K | 23.8K | |
| Share holders equity per share | 20.56K | 20.59K | 21.26K | 12.74K | 12.53K | |
| Interest debt per share | 22.9K | 23.16K | 21.45K | 11.61K | -136.06 | |
| Market cap | 3954.21B | 3760.99B | 3393.3B | 4065.9B | 4557.03B | |
| Enterprise value | 4501.94B | 4375.63B | 4032.46B | 4658.32B | 4557.03B | |
| P/E ratio | 74.64 | 670.46 | 42.08 | 49.68 | -180.62 | |
| Price to sales ratio | 11.44 | 8.23 | 6.39 | 8.02 | 8.81 | |
| POCF ratio | -109.3 | 119.73 | 174.01 | 45.67 | 217.74 | |
| PFCF ratio | -59.28 | -1.98K | -585.14 | 111.9 | -530.63 | |
| P/B Ratio | 4.28 | 4.06 | 3.55 | 3.97 | 4.52 | |
| PTB ratio | 4.28 | 4.06 | 3.55 | 3.97 | 4.52 | |
| EV to sales | 13.02 | 9.58 | 7.6 | 9.19 | 8.81 | |
| Enterprise value over EBITDA | 86.62 | 180.92 | 58.82 | 88.09 | -288.07 | |
| EV to operating cash flow | -124.43 | 139.3 | 206.78 | 52.32 | 217.74 | |
| EV to free cash flow | -67.49 | -2.31K | -695.35 | 128.2 | -530.63 | |
| Earnings yield | 0 | 0 | 0.01 | 0.01 | 0 | |
| Free cash flow yield | -0.02 | 0 | 0 | 0.01 | 0 | |
| Debt to equity | 0.24 | 0.47 | 0.45 | 0.42 | 0 | |
| Debt to assets | 0.49 | 0.49 | 0.47 | 0.45 | 0.46 | |
| Net debt to EBITDA | 10.54 | 25.41 | 9.32 | 11.2 | 0 | |
| Current ratio | 1.34 | 1.6 | 1.7 | 1.54 | 1.36 | |
| Interest coverage | 2.02 | 1.91 | 10.92 | -2.61 | -0.9 | |
| Income quality | -2.73 | 22.4 | 0.97 | 4.35 | -3.32 | |
| Dividend Yield | 0 | 0.01 | 0 | 0 | 0.01 | |
| Payout ratio | 0.27 | 20.42 | 0 | 0 | -4.76 | |
| Sales general and administrative to revenue | 0.03 | 0.02 | 0.02 | 0.03 | 0.31 | |
| Research and developement to revenue | 0.08 | 0.06 | 0.08 | 0.1 | 0 | |
| Intangibles to total assets | 0.1 | 0.1 | 0.1 | 0.15 | 0 | |
| Capex to operating cash flow | 0.84 | -1.06 | -1.3 | -0.59 | -1.41 | |
| Capex to revenue | -0.09 | -0.07 | -0.05 | -0.1 | -0.06 | |
| Capex to depreciation | -2.05 | -2.43 | -1.43 | -3.27 | -1.64 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 11.68K | 3.8K | 14.64K | 8.53K | 4.7K | |
| ROIC | 0.01 | 0.01 | 0.03 | -0.01 | 0 | |
| Return on tangible assets | 0 | 0 | 0.01 | 0.01 | 0 | |
| Graham Net | -18.66K | -19.8K | -20.29K | -11.6K | -20.1K | |
| Working capital | 390.32B | 548.52B | 606.46B | 498.95B | 360.63B | |
| Tangible asset value | 1359.89B | 1363.16B | 1427.43B | 1377.48B | 0 | |
| Net current asset value | -109.41B | -164.51B | -95.26B | -161.24B | -254.06B | |
| Invested capital | 1.11 | 1.12 | 1 | 0.9 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 52.91 | 35.34 | 37.15 | 37.7 | 0 | |
| Days of inventory on hand | 217.47 | 152.72 | 145.29 | 128.31 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.7 | 2.55 | 2.42 | 2.39 | 0 | |
| Inventory turnover | 0.41 | 0.59 | 0.62 | 0.7 | 0 | |
| ROE | 0.01 | 0 | 0.02 | 0.02 | -0.01 | |
| Capex per share | -679.38 | -741.27 | -562.17 | -654.54 | -366.61 |
Frequently Asked Questions
What is Green Cross Holdings Corporation stock symbol ?
Green Cross Holdings Corporation is a US stock and trading under the symbol 005257.KS
What is Green Cross Holdings Corporation stock quote today ?
Green Cross Holdings Corporation stock price is $42150 today.
Is Green Cross Holdings Corporation stock public?
Yes, Green Cross Holdings Corporation is a publicly traded company.
Company Profile
- Volume Average 3.53K
- Market Capitalization 752.13B
- Employee 154
- Headquarters Yongin-Si,US
- IPO Date 2000-01-04
-
Website
https://www.greencross.com 
Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies. Green Cross Holdings was founded in 1967 and is headquartered in Yongin, South Korea.
